210 related articles for article (PubMed ID: 15014451)
41. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Danielsson A; Dzojic H; Nilsson B; Essand M
Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
[TBL] [Abstract][Full Text] [Related]
42. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
[TBL] [Abstract][Full Text] [Related]
43. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.
Jiang H; Alemany R; Gomez-Manzano C; Medrano DR; Lemoine MG; Olson MV; Alonso MM; Lee OH; Conrad CC; Yung WK; Fueyo J
Neoplasia; 2005 Aug; 7(8):723-9. PubMed ID: 16207474
[TBL] [Abstract][Full Text] [Related]
44. Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors.
Howe JA; Pelka P; Antelman D; Wilson C; Cornell D; Hancock W; Ramachandra M; Avanzini J; Horn M; Wills K; Sutjipto S; Ralston R
Virology; 2006 Feb; 345(1):220-30. PubMed ID: 16246392
[TBL] [Abstract][Full Text] [Related]
45. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
Wei F; Wang H; Chen X; Li C; Huang Q
Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
[TBL] [Abstract][Full Text] [Related]
46. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy.
Hsu KF; Wu CL; Huang SC; Hsieh JL; Huang YS; Chen YF; Shen MR; Chung WJ; Chou CY; Shiau AL
Cancer Gene Ther; 2008 Aug; 15(8):526-34. PubMed ID: 18497852
[TBL] [Abstract][Full Text] [Related]
47. Adenovirus E1B 19K protein is required for efficient DNA replication in U937 cells.
Hu MC; Hsu MT
Virology; 1997 Jan; 227(2):295-304. PubMed ID: 9018128
[TBL] [Abstract][Full Text] [Related]
48. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
49. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
50. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
Saito Y; Sunamura M; Motoi F; Abe H; Egawa S; Duda DG; Hoshida T; Fukuyama S; Hamada H; Matsuno S
Cancer Gene Ther; 2006 Mar; 13(3):242-52. PubMed ID: 16179928
[TBL] [Abstract][Full Text] [Related]
52. Bovine adenovirus type 3 E1B(small) protein is essential for growth in bovine fibroblast cells.
Zhou Y; Reddy PS; Babiuk LA; Tikoo SK
Virology; 2001 Sep; 288(2):264-74. PubMed ID: 11601898
[TBL] [Abstract][Full Text] [Related]
53. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ
Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644
[TBL] [Abstract][Full Text] [Related]
54. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication.
Fechner H; Wang X; Srour M; Siemetzki U; Seltmann H; Sutter AP; Scherübl H; Zouboulis CC; Schwaab R; Hillen W; Schultheiss HP; Poller W
Gene Ther; 2003 Sep; 10(19):1680-90. PubMed ID: 12923567
[TBL] [Abstract][Full Text] [Related]
55. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.
Farson D; Tao L; Ko D; Li Q; Brignetti D; Segawa K; Mittelstaedt D; Harding T; Yu DC; Li Y
Mol Ther; 2006 Aug; 14(2):305-11. PubMed ID: 16697707
[No Abstract] [Full Text] [Related]
56. Resistance to retransformation by adenovirus but not by heterologous oncogenes in an E1-positive transformation revertant cell line may be mediated by a cellular function.
Sircar S; Rodrigues M; Weber JM
Oncogene; 1988 Dec; 3(6):725-8. PubMed ID: 2577877
[TBL] [Abstract][Full Text] [Related]
57. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
58. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
Hannay J; Davis JJ; Yu D; Liu J; Fang B; Pollock RE; Lev D
Gene Ther; 2007 Apr; 14(8):671-81. PubMed ID: 17287860
[TBL] [Abstract][Full Text] [Related]
59. [Structure of integrated oncogens E1A and E1B in a malignant line of rat SH2 fibroblasts, transformed by monkey adenovirus SA7 (C8) DNA].
Surin VL; Sats NV; Tagiev AF
Mol Biol (Mosk); 1994; 28(2):350-4. PubMed ID: 8183267
[TBL] [Abstract][Full Text] [Related]
60. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
